Kusec, Andrea
Milosevich, Elise
Williams, Owen A.
Chiu, Evangeline G.
Watson, Pippa
Carrick, Chloe
Drozdowska, Bogna A.
Dillon, Avril
Jennings, Trevor
Anderson, Bloo
Dawes, Helen
Thomas, Shirley
Kuppuswamy, Annapoorna
Pendlebury, Sarah T.
Quinn, Terence J.
Demeyere, Nele
Funding for this research was provided by:
Stroke Association (SA PPA 18/100032, SA PPA 18/100032, SA PPA 18/100032, SA PPA 18/100032, SA PPA 18/100032)
NIHR Exeter Biomedical Research Centre
NIHR Oxford Biomedical Research Centre (NIHR302224)
Article History
Received: 19 May 2023
Accepted: 10 November 2023
First Online: 30 November 2023
Declarations
:
: This study received ethical approval from the Health Research Authority—South Central Berkshire Research Ethics Committee approved this study (REC Reference: 19/SC/0520). All methods were conducted in accordance with the Declaration of Helsinki. All participants provided informed consent to participate in the study.
: Not applicable.
: ND is a developer of the Oxford Cognitive Screen but does not receive any remuneration from its use. TJQ chairs the DMC for a vascular cognitive impairment trial supported by NovoNordisk; TJQ has provided outcomes assessment and advisory board input for trials in cognition for Novartis, NovoNordisk. All other authors declare no competing interests.